Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More
PM360
SEPTEMBER 21, 2023
In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market. This product would be a more potent prescription version than the OTCs, Casberg notes. Another naloxone product is over-the-counter (OTC) Narcan by Emergent Biosciences.
105 
Let's personalize your content